BKM120 Phase 1: A new Novartis PI3K inhibitor, BMK120, is now recruiting at Sarah Cannon in Nashville, Tenn. As with most Phase 1 trials, this trial is for “Solid Tumors” which should include GIST. BMK120 inhibits PI3K but unlike the other Novartis PI3K inhibitors, BEZ235 and BGT226, it does not also inhibit mTOR.

Nilotinib Versus Imatinib: 15 new sites are listed as recruiting in Austria, Brazil, Canada and Japan

First Line Options for Advanced GIST

Figures 1 and 2 represent an overview of first-line options for advanced GIST in the United States and internationally.

First line trials represent a new opportunity for GIST patients to try to improve on their initial treatment.
Options for Resistant GIST

**Figure 3: United States**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Phase</th>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib or Sunitinib</td>
<td>1</td>
<td>KIT / PDGFRA</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>2</td>
<td>KIT / PDGFRA / VEGF / RAF</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>3</td>
<td>KIT / PDGFRA / SRC</td>
</tr>
<tr>
<td>BIIB021</td>
<td></td>
<td>HSP-90</td>
</tr>
<tr>
<td>Nilotinib</td>
<td></td>
<td>KIT/PDGFRA</td>
</tr>
<tr>
<td>Doxorubicin + Flavopiridol</td>
<td></td>
<td>CDK</td>
</tr>
<tr>
<td>SF1126</td>
<td></td>
<td>P13K</td>
</tr>
</tbody>
</table>

**Figure 4: International**

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Phase</th>
<th>Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib or Sunitinib</td>
<td>1</td>
<td>KIT / PDGFRA</td>
</tr>
<tr>
<td>Imatinib + RAD001</td>
<td>2</td>
<td>KIT / PDGFRA / mTOR</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>3</td>
<td>KIT / PDGFRA / VEGF</td>
</tr>
<tr>
<td>Oral Angiogenesis Inhibitors</td>
<td></td>
<td>VEGF</td>
</tr>
<tr>
<td>Nilotinib</td>
<td></td>
<td>KIT/PDGFRA</td>
</tr>
<tr>
<td>Imatinib + IL-2</td>
<td></td>
<td>Immune System Response</td>
</tr>
<tr>
<td>Multi-Bacteria Vaccine</td>
<td></td>
<td>Immune System Response</td>
</tr>
</tbody>
</table>

Figures 3 and 4 provide an overview of the available clinical trial options for Gleevec resistant GIST. Some trials require resistance to Sutent as well.

Check the actual trial listing for details about eligibility. Several trials are for patients that are resistant to 400 mg of Gleevec but have not yet tried 800 mg.

Don't forget to check out the LRG Newsletter at www.gistnews.org for the most up-to-date information on GIST research, advocacy issues and the GIST community.
Note: Trials are first grouped together by treatment phase. For example, the first grouping lists 2 trials that are open to patients in all treatment stages. Each trial description also lists the treatment stage under the "Stage" heading. Trials that are specifically for GIST are listed first. Trials are then sorted by phase in descending order) and then by drug name. Trial sites are sorted by country, state and then city.

<table>
<thead>
<tr>
<th>Treatment Stage:</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imatinib</strong></td>
<td></td>
</tr>
<tr>
<td><em>Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor</em></td>
<td></td>
</tr>
<tr>
<td>Phase:</td>
<td>2</td>
</tr>
<tr>
<td>Stage:</td>
<td>All</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>KIT/PDGFRA inhibitor</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00764595</td>
</tr>
<tr>
<td>Contact:</td>
<td>See site contact info below</td>
</tr>
<tr>
<td>Niigata University Medical and Dental School</td>
<td></td>
</tr>
<tr>
<td>Niigata, Japan</td>
<td></td>
</tr>
<tr>
<td>81-25-227-2228</td>
<td></td>
</tr>
<tr>
<td>Tatsuo Kanda, MD</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment Stage:</th>
<th>First-line</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imatinib + Bevacizumab</strong></td>
<td></td>
</tr>
<tr>
<td><em>Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor</em></td>
<td></td>
</tr>
<tr>
<td>Phase:</td>
<td>3</td>
</tr>
<tr>
<td>Stage:</td>
<td>First-line</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT Block tumor blood vessel growth</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00324987</td>
</tr>
<tr>
<td>Contact:</td>
<td>See each trial site.</td>
</tr>
<tr>
<td>USC/Norris Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Los Angeles, CA USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office</td>
<td></td>
</tr>
<tr>
<td>323-865-0451</td>
<td></td>
</tr>
<tr>
<td>Lombardi CCC at Georgetown University</td>
<td></td>
</tr>
<tr>
<td>Washington, DC USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office</td>
<td></td>
</tr>
<tr>
<td>202-444-0381</td>
<td></td>
</tr>
<tr>
<td>Iowa Oncology Research Association - CCOP</td>
<td></td>
</tr>
<tr>
<td>Des Moines, IA USA</td>
<td></td>
</tr>
<tr>
<td>515-244-7586</td>
<td></td>
</tr>
<tr>
<td>Hedy Kindler, MD</td>
<td></td>
</tr>
<tr>
<td>Roscoe F. Morton, MD</td>
<td></td>
</tr>
<tr>
<td>University of Chicago</td>
<td></td>
</tr>
<tr>
<td>Chicago, IL USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office, 773-834-7424</td>
<td></td>
</tr>
<tr>
<td>John W. Goodwin, MD</td>
<td></td>
</tr>
<tr>
<td>Metro Minnesota - CCOP</td>
<td></td>
</tr>
<tr>
<td>St. Louis Park, MN USA</td>
<td></td>
</tr>
<tr>
<td>502-993-1517</td>
<td></td>
</tr>
<tr>
<td>Lombardi CCC at Georgetown University</td>
<td></td>
</tr>
<tr>
<td>Washington, DC USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office</td>
<td></td>
</tr>
<tr>
<td>202-444-0381</td>
<td></td>
</tr>
<tr>
<td>Iowa Oncology Research Association - CCOP</td>
<td></td>
</tr>
<tr>
<td>Des Moines, IA USA</td>
<td></td>
</tr>
<tr>
<td>515-244-7586</td>
<td></td>
</tr>
<tr>
<td>Hedy Kindler, MD</td>
<td></td>
</tr>
<tr>
<td>Roscoe F. Morton, MD</td>
<td></td>
</tr>
<tr>
<td>University of Chicago</td>
<td></td>
</tr>
<tr>
<td>Chicago, IL USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office, 773-834-7424</td>
<td></td>
</tr>
<tr>
<td>John W. Goodwin, MD</td>
<td></td>
</tr>
<tr>
<td>Metro Minnesota - CCOP</td>
<td></td>
</tr>
<tr>
<td>St. Louis Park, MN USA</td>
<td></td>
</tr>
<tr>
<td>502-993-1517</td>
<td></td>
</tr>
<tr>
<td>Lombardi CCC at Georgetown University</td>
<td></td>
</tr>
<tr>
<td>Washington, DC USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office</td>
<td></td>
</tr>
<tr>
<td>202-444-0381</td>
<td></td>
</tr>
<tr>
<td>Iowa Oncology Research Association - CCOP</td>
<td></td>
</tr>
<tr>
<td>Des Moines, IA USA</td>
<td></td>
</tr>
<tr>
<td>515-244-7586</td>
<td></td>
</tr>
<tr>
<td>Hedy Kindler, MD</td>
<td></td>
</tr>
<tr>
<td>Roscoe F. Morton, MD</td>
<td></td>
</tr>
<tr>
<td>University of Chicago</td>
<td></td>
</tr>
<tr>
<td>Chicago, IL USA</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials Office, 773-834-7424</td>
<td></td>
</tr>
<tr>
<td>John W. Goodwin, MD</td>
<td></td>
</tr>
</tbody>
</table>
Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

- **Phase:** 3
- **Stage:** First-line
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** KIT/PDGFRA inhibitor
- **Strategy:** Block KIT
- **NCT #:** NCT00812240
- **Contact:** Centre Oscar Lambret
  Antoine Adenis, M.D.
  a-adenis@o-lambret.fr
  +33 (0) 3 20 29 59 59
  **Hospital Jean Minjoz**
  Besancon, France

- **Institut Bergonie**
  Bordeaux, France
  Binh Bui Nguyen, MD

- **Centre Georges Francois Leclerc**
  Dijon, France

- **Centre Hospitalier Victor Jousselin**
  Dreux, France

- **Centre Oscar Lambret - Lille**
  Lille, France
  Antoine Adenis, MD

- **Centre Leon Berard**
  Lyon, France
  +33607507064
  blay@lyon.fnclcc.fr
  Jean Yves-Blay, MD, PhD

- **Institut Paoli Calmette**
  Marseilles, France
  Patrice Viens, MD, PhD

- **Centre Val d’Aurele**
  Montpellier, France

- **Centre Rene Gauducheau**
  Nantes, France

- **Hopital de la Source**
  Orleans, France

- **Hopital European Georges Pompidou**
  Paris, France

- **Hopital Robert Debre**
  Reims, France

- **Hopital Charles Nicolle**
  Rouen, France

- **Centre Rene Huguenin**
  Saint-Cloud, France

- **Hopital Saint-Georges**
  Beirut, Lebanon

- **American University Hospital**
  Beirut, Lebanon

- **Middle East Institute of Health**
  Bsalim, Lebanon

- **Hopital Saint-Joseph**
  Dora, Lebanon

- **Hamoud Hospital**
  Saida, Lebanon

- **MD Anderson - Orlando**
  Orlando, FL USA

- **Henry Ford Health System**
  Detroit, MI USA

- **Beth Israel Medical Center**
  New York, NY USA
Nilotinib or Imatinib
Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

Phase: 3
Stage: First-line
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/ PDGFRA inhibitor
Strategy: Block KIT

NCT #: NCT00785785
Contact: Novartis Pharmaceuticals
+1-800-340-6843

Universitätsklinik f. Innere Medizin Onkologische Ambulanz
Innsbruck, Austria
Annaliese Gachter
+43 512 504 23333
annaliese.gachter@uki.at
Eisterer Wolfgang, MD

Universitätsklinik f. Innere Medizin I
Vienna, Austria
Thomas Brodowicz, MD
+43-40400-4466
+43-40400-4685
Thomas Brodowicz, MD

Hotel Dieu du Quebec
Quebec, Canada
Ann Wright
1-418-691-2950
Felix Couture, MD

Ottawa Regional Cancer Center University of Ottawa
Ottawa, Ontario Canada
Tim Asmis, MD
613-737-7700 ext 70316
Tim Asmis, MD

Maisonneuve-Rosemont Hospital
Montreal, QC Canada
Jacinthe Lasalle, MD
514-252-3400 ext 4670
Lucas Sideris, MD

CHUM - Hopital Notre-Dame
Montreal, Quebec Canada
Chantal Gosselin
514-890-8000 ext. 24892
Denis Soulieres, MD

CHUS - Hospital Fleurimont
Sherbrooke, Quebec Canada
Brigitte Jean
1-819-346-1110 ext. 12872
Rami Kotb, MD

Aichi Cancer Center Hospital
Aichi, Japan
Akira Sawaki, MD
+81-52-762-6111
jutaku_a@aichi-cc.jp
Akira Sawaki, MD

National Cancer Center Hospital East
Chiba, Japan
Toshihiko Doi, MD
+81-4-7133-1111
tdoi@east.ncc.go.jp
Toshihiko Doi, MD

Hokkaido University Hospital
Hokkaido, Japan
Yoshito Komatsu
+81-11-706-5657
Yoshito Komatsu, MD

Kanagawa Cancer Center Hospital
Kanagawa, Japan
Haruhiko Cho, MD
+81-45-391-5791
Haruhiko Cho, MD

Kumamoto University Hospital
Kumamoto, Japan
Hideo Baba, MD
+81-96-344-2111
hдобaba@kumamoto-u.ac.jp
Hido Baba, MD

Niigata University Medical and Dental School
Niigata, Japan
Tatsuo Kanda, MD
+81-25-227-0372
kandat@med.niigata-u.ac.jp
Tatsuo Kanda, MD

National Hospital Organization - Osaka General Hospital
Osaka, Japan
Toshimasa Tsujinaka, MD
+81 6 6942 1331
toshi@ohnh.go.jp
Toshimasa Tsujinaka, MD

Osaka University Hospital
Osaka, Japan
Toshiro Nishida, MD
+81-6-6879-5111
toshin@surg1.med.osaka-u.ac.jp
Toshiro Nishida, MD

Shizouka Cancer Center
Shizuoka, Japan
Yusuke Onozawa
+81-55-989-5222
y.onozawa@sechr.jp
Yusuke Onozawa, MD

National Cancer Center Hospital
Tokyo, Japan
Yasuhide Yamada, MD
+81 3 542 5111
yayamada@ncc.go.jp
Yasuhide Yamada, MD

Consorci Hospitalari Parc Taulí
Barcelona, Spain
Jose G. Ruiz
+34-937-242-579
jgarcia@tauli.cat
Charles Pericay, MD

University Hospital La Paz
Madrid, Spain
Cristobal Belda-Iniesta, MD
34-1-2071138
cbelda.hulp@salud.madrid.org
Cristobal Belda-Iniesta, MD

Chulalongkorn University
Bangkok, Thailand
Virote Sriuranpong, MD
+66-2-256-4533
vsmtcu40@gmail.com
Virote Sriuranpong, MD

Siriraj Hospital
Bangkok, Thailand
Vichien Srimuninnimit, MD
+66-2-419-4488
vsmuninnimit@gmail.com
Vichien Srimuninnimit, MD

Prince of Songkla University
Songkla, Thailand
Patrapim Sunpaweravong, MD
+66-74-451-469
patrapim@medicine.psu.ac.th
Patrapim Sunpaweravong, MD

City of Hope
Duarte, CA USA
Neeti Arora
626-396-2900 xt 63019
narora@coh.org
Warren Chow, MD

City of Hope - Pasadena
Pasadena, CA USA
Doni Woo, RN
626-396-2900
Mark McNamara, MD
Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

- **Phase**: 2
- **Stage**: First-line
- **Conditions**: Gastrointestinal Stromal Tumor
- **Drug Type**: KIT/PDGFRα inhibitor + SRC inhibitor
- **Strategy**: Block KIT + Block KIT Signal Path
- **NCT #**: NCT00568750
- **Contact**: See site contact info below

Centre Hospitale Universitaire Vaudois
Lausanne, Switzerland
41-21-314-0150
Michael Montemurro, MD

Nilotinib

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)

- **Phase**: 2
- **Stage**: First-line
- **Conditions**: Gastrointestinal Stromal Tumor
- **Drug Type**: KIT/PDGFRα inhibitor
- **Strategy**: Block KIT
- **NCT #**: NCT00756509
- **Contact**: Novartis Basel + 41 61 324 1111

Site name unknown, Bad Saarow
Bad Saarow, Germany

Sunitinib or Imatinib

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg)

- **Phase**: 3
- **Stage**: Gleevec-resistant
- **Conditions**: Gastrointestinal Stromal Tumor
- **Drug Type**: KIT/PDGFRα inhibitor
- **Strategy**: Block KIT
- **NCT #**: NCT00372567
- **Contact**: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753
PfizerCancerTrials@emergin gmed.com
1-800-718-1021

Site name unknown, Goettingen 37075
Goettingen, Germany

Site name unknown, Mannheim 68135
Mannheim, Germany

Southwest German Cancer Center at Eberhard-Karls University
Tuebingen, Germany 49-707-1298-2127
joerg.hartmann@med.uni- tuebingen.de
Joerg T. Hartmann, MD

Site name unknown, Lai Chi Kok 0
Lai Chi Kok, Kowloon Hong Kong SAR

Site name unknown, Tuen Mun 0
Tuen Mun, New Territories Hong Kong SAR

Site name unknown, Bologna 40138
Bologna, Italy

Istituto Nazionale Dei Tumori
Milan, Italy
Paolo Casali MD
<table>
<thead>
<tr>
<th>Site name unknown, San Giovanni Rotondo 71013</th>
<th>Site name unknown, Farmington Hills 48334</th>
</tr>
</thead>
<tbody>
<tr>
<td>San Giovanni Rotondo, Foggia Italy</td>
<td>Farmington Hills, MI USA</td>
</tr>
<tr>
<td>Site name unknown, Seoul 135-710</td>
<td>Site name unknown, Henderson 89074</td>
</tr>
<tr>
<td>Seoul, Republic of Korea</td>
<td>Henderson, NV USA</td>
</tr>
<tr>
<td>Site name unknown, Seoul 138-736</td>
<td>Site name unknown, Las Vegas 89102</td>
</tr>
<tr>
<td>Seoul, Republic of Korea</td>
<td>Las Vegas, NV USA</td>
</tr>
<tr>
<td>Site name unknown, Seoul 110-744</td>
<td>Site name unknown, Las Vegas 89106</td>
</tr>
<tr>
<td>Seoul, Republic of Korea</td>
<td>Las Vegas, NV USA</td>
</tr>
<tr>
<td>Site name unknown, Barcelona 08036</td>
<td>Site name unknown, Las Vegas 89148</td>
</tr>
<tr>
<td>Barcelona, Spain</td>
<td>Las Vegas, NV USA</td>
</tr>
<tr>
<td>Site name unknown, Valencia 46009</td>
<td>Cleveland Clinic Taussig Cancer Center</td>
</tr>
<tr>
<td>Valencia, Spain</td>
<td>Cleveland, OH USA</td>
</tr>
<tr>
<td>Site name unknown, Glasgow G12 0YH</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Glasgow, UK</td>
<td>Philadelphia, PA USA</td>
</tr>
<tr>
<td>Royal Marsden Hospital</td>
<td></td>
</tr>
<tr>
<td>London, UK</td>
<td>1-888-FOX-CHASE</td>
</tr>
<tr>
<td>Site name unknown, London NW1 2PG</td>
<td>Contact: Novartis Basel</td>
</tr>
<tr>
<td>London, UK</td>
<td>41 61 324 1111</td>
</tr>
<tr>
<td>Christie Hospital NHS Trust</td>
<td>Site name unknown, Bad Saarow</td>
</tr>
<tr>
<td>Manchester, Lancashire UK</td>
<td>Bad Saarow, Germany</td>
</tr>
<tr>
<td>Evanston Hospital</td>
<td>Site name unknown, Dusseldorf</td>
</tr>
<tr>
<td>Evanston, IL USA</td>
<td>Dusseldorf, Germany</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Site name unknown, Essen</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Essen, Germany</td>
</tr>
<tr>
<td>Glenbrook Hospital</td>
<td>Site name unknown, Frankfurt</td>
</tr>
<tr>
<td>Glenview, IL USA</td>
<td>Frankfurt, Germany</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Site name unknown, Hannover</td>
</tr>
<tr>
<td>Highland Park Hospital</td>
<td>Hannover, Germany</td>
</tr>
<tr>
<td>Highland Park, IL USA</td>
<td>Site name unknown, Koln</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Koln, Germany</td>
</tr>
<tr>
<td>Karmanos Cancer Institute</td>
<td>Site name unknown, Mannheim</td>
</tr>
<tr>
<td>Detroit, MI USA</td>
<td>Mannheim, Germany</td>
</tr>
<tr>
<td>all (800) KARMANOS (1-800-527-6266) or e-mail</td>
<td>Site name unknown, Munchen</td>
</tr>
<tr>
<td><a href="mailto:info@karmanos.org">info@karmanos.org</a>. Anthony Sheilds, MD</td>
<td>Munchen, Germany</td>
</tr>
<tr>
<td>BIIB021 (CNF2024)</td>
<td>Site name unknown, Tubingen</td>
</tr>
<tr>
<td>An Open-Label, 18FDG-PET</td>
<td>Tubingen, Germany</td>
</tr>
<tr>
<td>Pharmacodynamic Assessment of the</td>
<td></td>
</tr>
<tr>
<td>Effect of BIIB021 in Subjects With</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal Stromal Tumors</td>
<td></td>
</tr>
<tr>
<td>Phase: 2</td>
<td></td>
</tr>
<tr>
<td>Stage: Gleevec-resistant</td>
<td></td>
</tr>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td></td>
</tr>
<tr>
<td>Drug Type: HSP90 inhibitor</td>
<td></td>
</tr>
<tr>
<td>Strategy: Destroy KIT</td>
<td></td>
</tr>
<tr>
<td>NCT #: NCT00618319</td>
<td></td>
</tr>
<tr>
<td>Contact: Biogen Idec <a href="mailto:oncologyclinicaltrials@biogenidec.com">oncologyclinicaltrials@biogenidec.com</a></td>
<td></td>
</tr>
<tr>
<td>Site name unknown, Rochester</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td>Rochester, MN USA</td>
<td>New York, NY USA</td>
</tr>
<tr>
<td>Robert Maki, MD</td>
<td></td>
</tr>
</tbody>
</table>
Nilotinib

Nilotinib in Advanced GIST

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: NCT00782834
Contact: See site contact info below

Fox Chase Cancer Center
Philadelphia, PA USA
1-888-FOX-CHASE (369-2427)
Margaret von Mehren, M.D.

Nilotinib

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Progression During Treatment With Imatinib

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: NCT00633295
Contact: Novartis Basel
41 61 324 1111
Site name unknown, Tel Aviv
Tel Aviv, Israel

Site name unknown, Tel Hashomer
Tel Hashomer, Israel

Sorafenib (Nexavar, BAY 43-9006)

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib + Sunitinib

Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRA inhibitor
Strategy: Block KIT
NCT #: NCT00265798
Contact: Clinical Trials Office - University of Chicago Cancer Research
773-834-7424
City of Hope
Duarte, CA USA
Warren A. Chow, MD, (866) 434-4673 xt 64215
Warren A. Chow, MD
USC-Norris Cancer Center
Los Angeles, CA USA
323-865-3955
lenz@hsc.usc.edu
Hein-Josef Lenz, M.D
UC-Davis
Sacramento, CA USA
916-734-3771
David Gandara, MD
University of Chicago
Chicago, IL USA
Clinical Trials Office, 773-834-7424
Hedy Kindler, MD
Cancer Care Specialists
Decatur, IL USA
James Wade III, MD, 217-876-6617,
jlwade3@sbcglobal.net
James Wade III, MD
Illinois CancerCare
Peoria, IL USA
John Kugler, MD, (309) 243-3605
John Kugler, MD
Central Illinois Hem/Onc
Springfield, IL USA
217-525-2500
Edem Agamah, MD

University of Michigan
Ann Arbor, MI USA
734 647-8925
Scott Schuetze, MD
Memorial Sloan-Kettering Cancer Center
New York, NY USA
David D’Adamo, MD, PhD, 212-639-7573
David D’Adamo, MD, PhD
Medical College of Wisconsin
Milwaukee, WI USA
414 805-4603
Stuart Wong, MD

Vanderbilt-Ingram Cancer Center-Cool Springs
Franklin, TN USA
615 343-4128
Jordan Berlin
Vanderbilt-Ingram Cancer Center at Franklin
Franklin, TN USA
615 343-4128
Jordan Berlin
Vanderbilt-Ingram Cancer Center
Nashville, TN USA
800 811-8480
Clinical Trials Office
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors

Phase: 4
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: VEGFR inhibitor (TKI)
Strategy: Block tumor blood vessel growth
NCT #: NCT00777504
Contact: See site contact info below

University Medical Center Nijmegen at Raboud
Nijmegen, Gelderland Netherlands
31 24 3610353
c.vanherpen@onco.umcn.nl
C.M.L van Herpen, MD, PhD

Dasatinib (BMS-354825)
Trial of Dasatinib in Advanced Sarcomas

Phase: 2
Stage: Gleevec-resistant
Conditions: Gastrointestinal Stromal Tumor
Drug Type: KIT/PDGFRα inhibitor + SRC inhibitor
Strategy: Block KIT + Block KIT Signal Path
NCT #: NCT00464620
Contact: Kathleen Granlund
kgranlund@sarctrials.org
734-930-7607

Arkansas Children's Hospital
Little Rock, AR USA
Bryce Warren
WarrenBryceA@uams.edu
Kimo Stine

City of Hope
Duarte, CA USA
Neeti Arora
626-256-4673 ext. 63019
NArora@coh.org
Warren Chow, MD

Cedars-Sinai Outpatient Cancer Center
Los Angeles, CA USA
Chi Vu
310-423-2133
CVu@csocce.com
Charles Forscher, MD

Stanford Cancer Center
Palo Alto, CA USA
Maria Ahem
650-725-6413
mahem@stanford.edu

Kristen Ganjoo, MD

Sarcoma Oncology Center
Santa Monica, CA USA
Vicky Chua
(310) 552-9999
vikychua@aol.com
Sant Chawla, MD

University of Iowa Hospitals and Clinics
Iowa City, IA USA
Melanie Frees, RN
319-356-1228
melanie-frees@uiowa.edu
Mohammed Milhem, MD

Kootenai Cancer Center
Coeur d'Alene, ID USA
Sheryl Golden
208-666-2093
golden@kmc.org
Brian Samuels, MD

Oncology Specialists, Park Ridge
Park Ridge, IL USA
Kathy Tolzien
847-268-8569
tolzien@oncmed.net
Pamela Kaiser, MD

Indiana University Simon Cancer Center
Indianapolis, IN USA
Kristen Potter, MS
317-278-6616
kpotter@iuui.edu
Daniel Rushing, MD

Massachusetts General Hospital
Boston, MA USA
Anthony Thomas
617-643-5411
athomas2@partners.org
Edwin Choy, MD

Dana Farber Cancer Institute
Boston, MA USA
Sarah Solomon
617-582-7503
ssolomon1@partners.org
James Butynski, MD

Johns Hopkins Sidney Kimmel Comp Cancer Center
Baltimore, MD USA
Adult Oncology, 410-955-8804
Pediatric Oncology, 410-955-8751
David Loeb, MD, PhD

University of Michigan
Ann Arbor, MI USA
Gino Metko
734-647-2095
ginom@med.umich.edu
Scott Schuetze, MD, PhD

Nebraska Methodist Hospital
Omaha, NB USA
Gladys Pierce
402-334-5129
gladys.peirce@nmhs.org
Kirsten Leu, MD

Pennsylvania Oncology Hematology Associates
Philadelphia, PA USA
Deb Riordan, RN, BS
215-829-6712
debbierioira@penoncology.com

Arthur Staddon, MD

Fox Chase Cancer Center
Philadelphia, PA USA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

University of Pittsburgh Cancer Institute
Pittsburgh, PA USA
Lynne Frydrych
412-623-4036
frydrychlm2@upmc.edu

Hussein Tawbi, MD, MSc

MD Anderson Cancer Center
Houston, TX USA
Joanne Gigstad
713-553-0510
jgigstad@mdanderson.org
Shreyas Patel, MD
**Everolimus**

*Treatment of Patients With RAD001 Who Have Progressive Sarcoma*

- **Phase:** 2
- **Stage:** Gleevec-resistant Sarcoma
- **Drug Type:** mTOR inhibitor
- **Strategy:** Block KIT Signal Path
- **NCT #:** NCT00767819
- **Contact:** Novartis Pharmaceuticals +1 800-340-6843

<table>
<thead>
<tr>
<th>Site name unknown, Berlin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berlin, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site name unknown, Dusseldorf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dusseldorf, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site name unknown, Mannheim 68135</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannheim, Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site name unknown, Munchen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Munchen, Germany</td>
</tr>
</tbody>
</table>

**Imatinib + IL-2**

*Imatinib + IL-2*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** KIT inhibitor + Immune stimulate
- **Strategy:** Block KIT + Stimulate the immune system
- **NCT #:** See site contact info below
- **Contact:** Institut Gustave-Roussy
  Villejuif Cedex, France
  Patricia Pautier, MD
  33 (0) 1 42 11 42 11
  pautier@igr.fr
  Laurence Zitvogel, MD

**Multi-bacteria vaccine (MBV)**

*A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** Immune stimulate
- **Strategy:** Stimulate the immune system
- **NCT #:** NCT00623831
- **Contact:** See site contact info below
- **Contact:** Krankenhaus Nordwest
  Frankfurt, Germany
  Antje Neumann
  neumann.antje@khnw.de
  069 7601 4161
  Elke Jaeger, MD

**Doxorubicin + Flavopiridol**

*Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Gastrointestinal Stromal Tumor Sarcoma
- **Drug Type:** Transcription inhibitor + Chemotherapy
- **Strategy:** Freeze the cell division cycle
- **NCT #:** NCT00098579
- **Contact:** See site contact info below
- **Site name unknown, Bellinzona**
  Bellinzona, Switzerland

**SF1126**

*A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** PI3K inhibitor
- **Strategy:** Block KIT Signal Path
- **NCT #:** See site contact info below
- **Contact:** TGen Clinical Research Services
  Scottsdale, AZ USA
  480-323-1339
  jingold@shc.org
  Daniel D. Hoff, MD

**AUY922**

*Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2-Positive Malignancies*

- **Phase:** 1
- **Stage:** Gleevec-resistant
- **Conditions:** Solid Tumors
- **Drug Type:** HSP90 inhibitor
- **Strategy:** Destroy KIT
- **NCT #:** NCT00526045
- **Contact:** Novartis Pharmaceuticals +1 800-340-6843
  Site Name unknown, Bellinzona
  Bellinzona, Switzerland
**BGT226**

*A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer*

<table>
<thead>
<tr>
<th>Phase</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type</td>
<td>mTOR inhibitor, PI3K inhibitor</td>
</tr>
<tr>
<td>Strategy</td>
<td>Block KIT Signal Path</td>
</tr>
<tr>
<td>NCT #</td>
<td>NCT00600275</td>
</tr>
<tr>
<td>Contact</td>
<td>Novartis 800 340-6843</td>
</tr>
</tbody>
</table>

**Princess Margaret Hospital**
Toronto, ON Canada
Lillian Siu, M.D.

**Hospital Vall d'Hebron**
Barcelona, Spain

**Dana Farber Cancer Institute**
Boston, MA USA

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX USA
Jim Agnew, RN
Anthony Tolcher, MD

**MP470**

*Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470,*

<table>
<thead>
<tr>
<th>Phase</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type</td>
<td>KIT/PDGFRA inhibitor</td>
</tr>
<tr>
<td>Strategy</td>
<td>Block KIT</td>
</tr>
<tr>
<td>NCT #</td>
<td>NCT00894894</td>
</tr>
<tr>
<td>Contact</td>
<td>SuperGen Gil Fine, PhD 925-560-0100 <a href="mailto:gfine@supergen.com">gfine@supergen.com</a> Angelique Mittan, CLS 925-560-0100</td>
</tr>
</tbody>
</table>

**TGen Clinical Research Services**
Scottsdale, AZ USA

**SNX-5422**

*SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment*

<table>
<thead>
<tr>
<th>Phase</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type</td>
<td>HSP90 inhibitor</td>
</tr>
<tr>
<td>Strategy</td>
<td>Destroy KIT</td>
</tr>
<tr>
<td>NCT #</td>
<td>NCT00644072</td>
</tr>
<tr>
<td>Contact</td>
<td>Warren Grant Magnuson Clinical Center Bethesda, MD USA Clinical Trials Office 888-NCI-1937 Giuseppe Giaccone, MD, PhD</td>
</tr>
<tr>
<td><strong>AT13387</strong></td>
<td><strong>BEZ235</strong></td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>Phase 1 Study of HSP90 inhibitor AT13387 in solid tumors</strong></td>
<td><strong>A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer</strong></td>
</tr>
<tr>
<td><strong>Phase:</strong> 1</td>
<td><strong>Phase:</strong> 1</td>
</tr>
<tr>
<td><strong>Stage:</strong> Gleevec-resistant</td>
<td><strong>Stage:</strong> Gleevec-resistant</td>
</tr>
<tr>
<td><strong>Conditions:</strong> Solid Tumors</td>
<td><strong>Conditions:</strong> Solid Tumors</td>
</tr>
<tr>
<td><strong>Drug Type:</strong> HSP90 inhibitor</td>
<td><strong>Drug Type:</strong> mTOR inhibitor</td>
</tr>
<tr>
<td><strong>Strategy:</strong> Destroy KIT</td>
<td><strong>Strategy:</strong> Block KIT Signal Path</td>
</tr>
<tr>
<td><strong>NCT #:</strong> <a href="https://www.clinicaltrials.gov">NCT00878423</a></td>
<td><strong>NCT #:</strong> <a href="https://www.clinicaltrials.gov">NCT00620594</a></td>
</tr>
<tr>
<td><strong>Contact:</strong> Andrew Wolanski</td>
<td><strong>Contact:</strong> Novartis</td>
</tr>
</tbody>
</table>
| 617-632-6623 | 862-778-8300 | **Royal Marsden Hospital**
| Andrew_Wolanski@dfci.harvard.edu | Nevada Cancer Institute Las Vegas, NV USA
| [Beth Israel Deaconess Medical Center](https://www.bidmc.harvard.edu) | Dianna Tercan (702) 822-5483
| [Massachusetts General Hospital](https://www.mgh.harvard.edu) | Wolfram Samlowski, M.D. |
| [Dana Farber Cancer Institute](https://www.dana-farber.org) | Sarah Cannon Research Institute Nashville, TN USA |
| **BAY 73-4506** | **BAY 73-4506** | **BAY 73-4506** |
| **Phase 1 study of BAY 73-4506** | **Phase 1 study of BAY 73-4506** | **Phase 1 study of BAY 73-4506** |
| **Phase:** 1 | **Phase:** 1 | **Phase:** 1 |
| **Stage:** Gleevec-resistant | **Stage:** Gleevec-resistant | **Stage:** Gleevec-resistant |
| **Conditions:** Solid Tumors | **Conditions:** Solid Tumors | **Conditions:** Solid Tumors |
| **Drug Type:** KIT/PDGFR inhibitor VEGFR inhibitor (TKI) | **Drug Type:** HSP90 inhibitor | **Drug Type:** PI3K inhibitor |
| **Strategy:** Block KIT | **Strategy:** Destroy KIT | **Strategy:** Block KIT Signal Path |
| **NCT #:** See site contact info below | **NCT #:** [NCT00618735](https://www.clinicaltrials.gov) | **NCT #:** [NCT00876122](https://www.clinicaltrials.gov) |
| **Contact:** See site contact info below | **Contact:** Biogen Idec oncologyclinicaltrials@biogenidec.com | **Contact:** See site contact info below |
| **MD Anderson Cancer Center** Houston, TX USA Clinical Trials Office 713-792-3245 Jon Trent, MD, PhD | **Premier Oncology, Santa Monica** Santa Monica, CA USA | **Royal Marsden Hospital** London, UK Krunal Shah 0208 722 4005 Krunal.Shah@icr.ac.uk |
| **South Texas Accelerated Research Therapeutics (START)** San Antonio, TX USA Tracy Dufresne, RN 210-593-5265 tracy.dufresne@start.stoh.com | **South Texas Accelerated Research Therapeutics (START)** San Antonio, TX USA | **South Texas Accelerated Research Therapeutics (START)** San Antonio, TX USA |

**BKM120**

**A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** PI3K inhibitor  
**Strategy:** Block KIT Signal Path  
**NCT #:** [NCT00876122](https://www.clinicaltrials.gov)  
**Contact:** See site contact info below

**GDC-0941**

**A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard**

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** PI3K inhibitor  
**Strategy:** Block KIT Signal Path  
**NCT #:** [NCT00876122](https://www.clinicaltrials.gov)  
**Contact:** See site contact info below

**Royal Marsden Hospital** London, UK Krunal Shah 0208 722 4005 Krunal.Shah@icr.ac.uk
**GDC-0941**

An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** PI3K inhibitor  
**Strategy:** Block KIT Signal Path  
**NCT #:** NCT00876109  
**Contact:** See site contact info below  

TGen Clinical Research Services  
Scottsdale, AZ USA  
Lynne Hull  
480-323-1071  
LHull@SHC.org  
Daniel D. Hoff, MD  

Dana Farber Cancer Institute  
Boston, MA USA  
Melissa Hohos  
617 632-2201  
mhohos@partners.org  
George Demetri, MD, PhD  

Karmanos Cancer Institute  
Detroit, MI USA  
Jie Zhang  
313-576-9365  
zhangj@karmanos.org

**San Diego Pacific Oncology and Hematology Associates**  
Encinitas, CA USA  
Karen Brady, RN MSN  
760-752-3340  
kbrady@premiereoncology.com  
Richard Just, M.D.  

**Premier Oncology, Santa Monica**  
Santa Monica, CA USA  
Marilyn Mulay, NP  
310-633-8400  
mmulay@premiereoncology.com  
Lee Rosen M.D.  

**University of Colorado**  
Aurora, CO USA  
Stacy Grolnic, RN  
720-848-0655  
stacy.grolnic@uchsc.edu  
Colin Weekes, MD, PhD  

**Mary Crowley Medical Research Center (Central Office)**  
Dallas, TX USA  
Kay Easterwood-Sanchez  
214-658-1943  
Neil Senzer, MD

**PX-866**

Phase I Trial of Oral PX-866

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** PI3K inhibitor  
**Strategy:** Block KIT Signal Path  
**NCT #:** NCT00726583  
**Contact:** See site contact info below  

University of Colorado  
Aurora, CO USA  
Sharon hecker  
720-848-0667  
sharon.hecker@ucdenver.edu  
Antonio Jimeno, MD  

MD Anderson Cancer Center  
Houston, TX USA  
Rhonda Clement  
713-563-3559  
rlelement@mdanderson.org  
Roy Herbst, MD

**IPI-493**

A Phase I Dose Escalation Study of IPI-493

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** HSP90 inhibitor  
**Strategy:** Destroy KIT  
**NCT #:** NCT00724425  
**Contact:** See site contact info below  

TGen Clinical Research Services  
Scottsdale, AZ USA  
Lynne Hull  
480-323-1071  
LHull@SHC.org  
Daniel D. VonHoff, MD  

Hoffmann-La Roche  
Please reference Study ID Number: NO21200  
973-235-5000  
800-526-6367 (US only)

**R1507**

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors

**Phase:** 1  
**Stage:** Gleevec-resistant  
**Conditions:** Solid Tumors  
**Drug Type:** IGF1R inhibitor  
**Strategy:** Block related tumor signal paths  
**NCT #:** NCT00560144  
**Contact:** Hoffmann-La Roche  

**Premier Oncology, Scottsdale**  
Scottsdale, AZ USA  
Patricia Shannon, RN  
480 860-5000 xt 223  
pshannon@premiereoncology.com  
David Mendelson, M.D.

**Memorial Sloan-Kettering Cancer Center**  
New York, NY USA  
212-639-8267  
Dr. Tanya Trippett
**SNX-5422**

*Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: NCT00506805  
Contact: Pfizer Oncology Clinical Trial Information  
1-877-369-9753  
PfizerCancerTrials@emergin gmed.com  
Pfizer CT.gov Call Center  
1-800-718-1021  
Site name unknown, Bethesda 20982  
Bethesda, MD USA

**Sorafenib + Vorinostat**

*Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HDAC inhibitor + KIT/PDGFRA inhibitor  
Strategy: Block KIT + Unblock cell death genes + Destroy KIT  
NCT #: NCT00635791  
Contact: See site contact info below

**STA-9090**

*Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: NCT00687934  
Contact: See site contact info below

**STA-9090**

*Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: NCT00688116  
Contact: See site contact info below

---

**University of Pennsylvania**  
Philadelphia, PA USA

**MD Anderson Cancer Center**  
Houston, TX USA  
800-392-1611 Patients  
800-392-1611 Referring MD  
Cynthia E. Herzog

**STA-9090**

*Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: NCT00687934  
Contact: See site contact info below

**STA-9090**

*Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors*

Phase: 1  
Stage: Gleevec-resistant  
Conditions: Solid Tumors  
Drug Type: HSP90 inhibitor  
Strategy: Destroy KIT  
NCT #: NCT00688116  
Contact: See site contact info below

**University of Colorado**  
Aurora, CO USA  
Stacy Grolnic  
720-848-0655  
stacy.grolnic@uchsc.edu  
David Ross Camidge MD

---

**University of Colorado**  
Aurora, CO USA  
Stacy Grolnic  
720-848-0655  
stacy.grolnic@uchsc.edu  
David Ross Camidge MD

---

**University of Colorado**  
Aurora, CO USA  
Stacy Grolnic  
720-848-0655  
stacy.grolnic@uchsc.edu  
David Ross Camidge MD

---

**University of Colorado**  
Aurora, CO USA  
Stacy Grolnic  
720-848-0655  
stacy.grolnic@uchsc.edu  
David Ross Camidge MD
### Sunitinib + CP-751,871
**Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>Block KIT + Block related tumor signal paths</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT + Block related tumor signal paths</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00729833</td>
</tr>
<tr>
<td>Contact:</td>
<td>Exelixis Contact Line 866-939-4041</td>
</tr>
</tbody>
</table>

**Hospital Vall d’Hebron**
Barcelona, Spain
Gemma Sala
+34 93 489 4158
gsala@vhebron.net
Jose Baselga, MD, PhD

**Dana Farber Cancer Institute**
Boston, MA USA
Pilar de la Rocha Mur
617-632-5841
pilar_DeLaRochaMur@dfci.harvard.edu
Geoffrey Shapiro, MD

**Mary Crowley Medical Research Center (Baylor)**
Dallas, TX USA
J.R. Dolan
214-658-1943
Gerald Edelman MD, PhD

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX USA
Gina Mangold, MBA
210-413-3594
gmangold@start.stoh.com
Kyriakos Papadopoulos, MD

---

### XL147
**Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>PI3K inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT Signal Path</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00486135</td>
</tr>
<tr>
<td>Contact:</td>
<td>Exelixis Contact Line 866-939-4041</td>
</tr>
</tbody>
</table>

**Hospital Vall d’Hebron**
Barcelona, Spain
Gemma Sala
+34 93 489 4158
gsala@vhebron.net
Jose Baselga, MD, PhD

**Dana Farber Cancer Institute**
Boston, MA USA
Pilar de la Rocha Mur
617-632-5841
pilar_DeLaRochaMur@dfci.harvard.edu
Geoffrey Shapiro, MD

**Mary Crowley Medical Research Center (Baylor)**
Dallas, TX USA
J.R. Dolan
214-658-1943
Gerald Edelman MD, PhD

---

### XL765
**Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage:</td>
<td>Gleevec-resistant</td>
</tr>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Drug Type:</td>
<td>mTOR inhibitor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block related tumor signal paths</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00485719</td>
</tr>
<tr>
<td>Contact:</td>
<td>Exelixis Contact Line 866-939-4041</td>
</tr>
</tbody>
</table>

**Hospital Vall d’Hebron**
Barcelona, Spain
Gemma Sala +34 93 489 4158
gsala@vhebron.net
Jose Baselga, MD, PhD

**Karmanos Cancer Institute**
Detroit, MI USA
Theresa Laeder 313-576-9386
Patricia LoRusso, DO

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX USA
Gina Mangold, MBA 210-413-3594
gmangold@start.stoh.com
Kyriakos Papadopoulos, MD
**Radiation**

*Radiation Therapy as Palliative Treatment of GIST (GIST-RT)*

- **Phase:** 1
- **Stage:** Palliative
- **Conditions:** Gastrointestinal Stromal Tumor
- **Drug Type:** None
- **Strategy:** Radiation
- **NCT #:** NCT00515931
- **Contact:**
  - Helsinki University Central Hospital
  - Helsinki, Finland
  - 947173208 Ext. 358
  - heikki.joensuu@hus.fi
  - Heikki Joensuu, MD

---

**Sunitinib + Radiation**

*Sutent and Radiation as Treatment for LimitedExtent Metastatic Cancer*

- **Phase:** 2
- **Stage:** Palliative
- **Conditions:** Any type of Cancer
- **Drug Type:** KIT/PDGFRA inhibitor
- **Strategy:** Block KIT
- **NCT #:** NCT00463060
- **Contact:**
  - Mount Sinai School of Medicine
  - New York, NY USA
  - 212-241-7503
  - johnny.kao@mountsinai.org
  - Johnny Kao, MD